

Biocept

Completing the

Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2018

March 12, 2018

SAN DIEGO, March 12, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial results for the three months and 12 months ended December 31, 2017 after the market closes on Wednesday, March 28, 2018. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Biocept Logo (PRNewsFoto/Biocept, Inc.)

Individuals interested in participating on the conference call may do so by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4109 for other international callers. Those interested in listening to a webcast of the live conference call may do so by visiting <https://www.webcaster4.com/Webcast/Page/1271/24656>.

A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering the replay access code 10117300. A webcast replay will be available for 90 days at <http://ir.biocept.com/events.cfm>.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Cision View original content with multimedia: <http://www.prnewswire.com/news-releases/biocept-to-release-2017-fourth-quarter-and-full-year-financial-results-and-host-investor-conference-call-on-march-28-2018-300609756.html>

SOURCE Biocept, Inc.

Investor Contact: LHA Investor Relations: Jody Cain, Jcain@lhai.com, 310-691-7100; Media Contact: Trevelino/Keller: Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109